Korro Bio was founded to turn extraordinary scientific insights into life-altering new treatments for patients. We harness the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Our mission is to rewrite the future for patients living with debilitating disease by repairing the underlying genetic cause.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $207.5M
Founded date: 2018
Investors 3
| Date | Name | Website |
| 29.12.2021 | New Enterp... | nea.com |
| - | Atlas Vent... | atlasventu... |
| - | MP Healthc... | mp-healthc... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.01.2022 | Series B | $116M | - |
| 14.09.2020 | Series A | $91.5M | - |
Mentions in press and media 16
| Date | Title | Description |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 08.12.2024 | Atlas Venture: $450 Million Fund XIV Closed To Invest In Biotech Innovation | Atlas Venture—a leading early-stage venture capital firm investing in biotech innovation—announced closing its fourteenth fund, raising $450 million in an oversubscribed fundraise. Through Fund XIV, Atlas Venture will continue collaborating... |
| 06.01.2022 | Early stage startups doubled their funding in 2021 | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. It’s a great time to get an idea off the ground, particularly if you need some cash to get things... |
| 06.01.2022 | Early stage startups doubled their funding in 2021 | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. It’s a great time to get an idea off the ground, particularly if you need some cash to get things... |
| 06.01.2022 | Korro Bio secures $116M Series B | Korro Bio has raised $116 million in a round led by Eventide Asset Management. Based in the Boston area, the company is a developer of RNA therapeutics for patients with rare genetic diseases. Select Additional Investors Alexandria Venture ... |
| 05.01.2022 | Korro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine through its Pipeline of RNA Editing Programs | - |
| 05.01.2022 | Korro Bio Completes $116M Series B | CAMBRIDGE, MA, Korro Bio, an RNA editing company, announced the completion of a $116M Series B financing led by Eventide Asset Management. >> Click here for more funding data on Korro Bio >> To export Korro Bio funding data ... |
| 05.01.2022 | Korro Bio Closes $116M Series B Financing | Korro Bio, Inc., a Cambridge, Mass.-based RNA editing company focused on the discovery and development of novel genetic medicines, closed a $116M Series B financing. The round was led by Eventide Asset Management, with participation from ne... |
| 14.09.2020 | RNA Therapeutics Company Korro Bio Raises $91.5 Million | RNA therapeutics company Korro Bio announced recently that it has raised $91.5 million in a Series A funding round to advance its novel platform for precise and single-base RNA editing to modulate protein function for therapeutic applicatio... |
| 14.09.2020 | China’s Wu Capital leads $91.5m Series A round in genetic firm Korro Bio | Premium Cambridge-based biotech startup Korro Bio has raised $91.5 million in a Series A funding round led by Chinese investment firm Wu Capital to boost its gene-editing therapies. Continue reading this story with a subscription to DealStr... |
Show more